A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial Based on Standard Treatment to Evaluate the Effect of Injectable Neucardin on Cardiac Function and Reverse Ventricular Remodeling in Patients With Chronic Systolic Heart Failure
Latest Information Update: 29 Mar 2025
At a glance
- Drugs Recombinant human neuregulin 1-beta (Primary)
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Sponsors Zensun (Shanghai) Sci & Tech
Most Recent Events
- 28 Jan 2025 Status changed from recruiting to completed.
- 30 Jan 2024 Planned End Date changed from 1 Sep 2024 to 1 Aug 2024.
- 30 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jun 2024.